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Background: The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive
care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%.
Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter
thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate
locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for
patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus heparin
in terms of event-free survival of the first non-tunneled hemodialysis catheter inserted in ICU patients with AKI requiring
RRT. Secondary objectives are the rate of fibrinolysis, incidence of catheter thrombosis and catheter-related infection
per 1,000 catheter days, length of stay in ICU and in-hospital and 28-day mortality.
Methods/Design: The VERROU-REA study is a randomized, prospective, multicenter, double-blind, parallel-group,
controlled superiority study carried out in the medical, surgical and nephrological ICUs of two large university hospitals
in eastern France. A catheter lock solution composed of trisodium citrate at 4% will be compared to unfractionated
heparin at a concentration of 5,000 IU/mL. All consecutive adult patients with AKI requiring extracorporeal RRT, and in
whom a first non-tunneled catheter is to be inserted by the jugular or femoral approach, will be eligible. Catheters
inserted by the subclavian approach, patients with acute liver failure, thrombopenia or contraindication to systemic
anticoagulation will be excluded. Patients will be followed up daily in accordance with standard practices for RRT until
death or discharge.
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Discussion: Data is scarce regarding the use of non-tunneled catheters in the ICU setting in patients with AKI.
This study will provide an evidence base for recommendations regarding the use of anticoagulant catheter locks
for the prevention of dysfunction in non-tunneled hemodialysis catheters in patients with AKI in critical or
intensive care.
Trial registration: Registered with Clinicaltrials.gov (registration number: NCT01962116) on 27 August 2013.
Keywords: Citrate lock, Heparin lock, Catheter lock, Acute renal failure, Hemodialysis, Critically ill patientBackground
The incidence of acute kidney injury (AKI) varies ac-
cording to the populations studied and the definition
used, but it is estimated to be around 10 to 20% in pa-
tients admitted to the intensive care unit (ICU) [1-3].
The cause of AKI is most commonly acute tubular ne-
crosis occurring in the context of shock (septic and/or
cardiogenic), or drug toxicities (such as aminoglycosides
or contrast medium). The pathophysiology of AKI is well
established, and includes vascular, medullar and tubular
injury leading to a reduction in the rate of glomerular fil-
tration, and ultimately, anuria [4]. Renal replacement ther-
apy (RRT) can be required, depending on the AKI etiology
and comorbidities, particularly pre-existing renal insuffi-
ciency. In one observational study carried out among al-
most 30,000 ICU patients, the rate of RRT was around 4%
[3], but rates as high as 70 to 80% have been reported in
patients with shock [5-7]. Mortality in the ICU ranges
from 15 to 25%, but can reach 50 to 60% in patients with
AKI [3,8].
Venous catheters are currently the preferred vascular
access method for patients with AKI requiring extracor-
poreal RRT [9,10]. In critical care, non-tunneled catheters
represent standard practice. Despite the vast progress in
the management of AKI and high-quality catheter prac-
tices [11-13], vascular access remains the weak link in the
chain of RRT and contributes to increased morbidity in
hemodialysis patients, particularly through catheter dys-
function (stenosis and/or thrombosis) and infection.
Strategies to prevent hemodialysis catheter dysfunction
and infection include catheter locks, which are generally
either heparin or citrate. The principle of the catheter
lock is to instil an anticoagulant solution into the lumen of
the branches of the hemodialysis catheter after each RRT
session, leaving them in place until the next session.
Heparin locks are considered as the reference for non-
tunneled hemodialysis catheters, and are indicated in the
setting of RRT. Heparin exerts its anticoagulant effect by
binding to antithrombin and antagonizing anti-Xa and
anti-IIa activity, as well as all activated coagulation factors.
The anticoagulant effect of heparin renders it difficult to
handle in the ICU because of the associated bleeding risk
[14-16] and the risk of heparin-induced thrombocytopenia
[17-19]. Fibrinolysis in situ in the catheter has beenreported to be necessary in 3 to 9.5 per 1,000 catheter
days, reflecting the failure of anticoagulation and the
wide variations in heparin concentrations within the
catheter that can be observed with this drug [20,21].
Citrate is an alternative to heparin as a catheter lock
solution. Citrate exerts its anticoagulant effect by its
ability to chelate calcium, which is fundamental to the
activation of the coagulation cascade, but also of platelet
activity [22,23]. Citrate can prevent the formation of a
biofilm by calcium and magnesium chelating effects,
thus avoiding bacterial colonization [24-28]. Trisodium
citrate 4% is considered as the reference lock solution
for long-term tunneled catheters in patients undergoing
chronic hemodialysis, in order to prevent catheter dys-
function and infection [29,30]. It is noteworthy that in
2000, the Food and Drug Administration prohibited the
use of citrate at concentrations greater than 4% due to
the risk of metabolic disorders [31,32], notably major
hypocalcemia resulting in death [33] in cases of systemic
leakage. Conversely, bacterial resistance has never been
reported with citrate when used as a catheter lock solution.
There are few data from the literature reporting compar-
isons between citrate and heparin locks for patients with
non-tunneled catheters. Data mainly concern patients
undergoing chronic RRT with long-term tunneled cathe-
ters. These predominantly favored citrate locks for the
prevention of infectious and thrombotic risk [28,34-37].
To the best of our knowledge, only one randomized
study, which included 291 patients, has compared the
safety and efficacy of heparin versus citrate as a locking
solution for non-tunneled catheters in hemodialysis pa-
tients [15]. The risk of catheter dysfunction was signifi-
cantly lower in the citrate group, at 5 versus 8.1 events per
1,000 catheter days for citrate versus heparin respectively
(relative risk (RR) 0.38, P = 0.015). The authors also noted
a lower incidence of catheter infection in the citrate group
(1.4 out of 1,000 catheter days) as compared to the hep-
arin group (3.9 out of 1,000 catheter days) (RR 0.36, 95%
CI 0.13 to 1.00, P = 0.05). Furthermore, the risk of bleed-
ing and death from catheter-related bacteremia was sig-
nificantly lower in the citrate group. Indeed, it should
be noted that this study was prematurely interrupted
because of a significant difference in catheter-related
bacteremia between groups, in favor of the citrate group.
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used was 30% (instead of 4%), and patients in intensive or
critical care were excluded.
The primary objective of our study is to demonstrate
the superiority of trisodium citrate 4% over heparin as a
catheter lock solution, in terms of event-free survival of
the first non-tunneled hemodialysis catheter inserted in
patients hospitalized in intensive or critical care for AKI
requiring extracorporeal RRT. Secondary objectives are
to compare the rate of fibrinolysis, incidence of catheter
thrombosis and catheter-related infection per 1,000
catheter days, length of stay in an ICU, and in-hospital
and 28-day mortality.Methods/Design
Study design
The VERROU-REA study is a randomized, prospective,
multicenter, double-blind, parallel-group, controlled su-
periority study. The study is carried out in the medical
ICU, the neuro-trauma ICU and the nephrology ICU of
the University Hospital of Dijon, France, and in the med-
ical ICU, the surgical ICU, and the nephrology ICU of the
University Hospital of Besancon, France. Two strategies
will be compared. Firstly, the treatment under study is a
catheter locking solution composed of trisodium citrate at
4% (Citra-Lock, Dirinco AG, Bern, Switzerland). This
treatment is not currently approved for use in the context
of extracorporeal RRT in critically ill patients with non-
tunneled catheters. However, there are international rec-
ommendations for its use in chronic dialysis patients with
tunneled catheters [29,30]. Secondly, in the control group,
the catheter lock used will be unfractionated heparin at a
concentration of 5,000 IU/mL, used within the range of its
currently approved indications, namely prevention of co-
agulation in catheters used for extracorporeal circulation
and RRT.Ethical considerations
The study protocol was approved by the local independent
ethics committee (Comité de Protection des Personnes,
Est I) on 21 February 2013 under the number 2013/14
and EudraCT number 2013-000414-37, and by the Agence
National de Sécurité des Médicaments et des Produits
de Santé (ANSM, French national agency for the safety
of medical products and devices, approval number 2013-
000414-37). Specific insurance for the study has been
contracted by the sponsor from the Hospital Mutual In-
surance Company (policy number: 129234). Each patient
will provide written informed consent concerning the
study design and outcomes. If the information about the
study cannot be provided to the patient, his or her rela-
tives will be duly informed about the study.Study population
All consecutive patients, hospitalized in any one of the
participating units, with AKI requiring extracorporeal
RRT will be included in the study. Patients are screened
daily by the clinical research monitors and investigators
in each center.
Inclusion criteria
The inclusion criteria for the study are as follows: patients
aged over 18 years, in whom a first non-tunneled catheter
is to be inserted by the jugular or femoral approach by
medical staff in the participating department.
Exclusion criteria
The exclusion criteria are as follows: catheters inserted
by the subclavian approach, patients with a contraindi-
cation to systemic anticoagulation (active uncontrolled
bleeding, acute liver failure (Factor V < 30%), thrombope-
nia < 30,000/mm3 in the absence of planned correction), doc-
umented or suspected heparin-induced thrombocytopenia,
known allergy to citrate, documented systemic bacterial in-
fection not under treatment at the time of randomization,
patients not affiliated with a health insurance system (bene-
ficiary or dependent), pregnant patients or legally protected
adults (namely adults in lawful custody or requiring assist-
ance in the conduct of their own affairs or in respect of
whom power of attorney is registered).
Study conduct
Inclusions in the study started on 14 June 2013. All staff
likely to be involved in the management of patients in-
cluded in the VERROU-REA study have attended a
training session to undergo training in the monitoring
procedures, and posters outlining the main procedures
to remember are on permanent display in all participat-
ing departments. Time zero is when randomization is
performed.
Randomization procedure
Randomization will be performed directly through the
secure Tenalea™ internet-based software (Formsvision
BV, Abcoude, Netherlands) after identification of the in-
vestigator by a personal password, which will be commu-
nicated prior to initiation of the study. The treatment
algorithms have been determined by the study statistician
(Clinical Investigation Centre - Clinical Epidemiology/
Clinical Trials (CIC-EC), Dijon, France). The allocation
is based on a minimization technique taking into ac-
count the catheter insertion site (jugular or femoral),
type of dialysis (continuous or intermittent) and Simplified
Acute Physiology Score (< 55 or ≥ 55) [38]. Patients are
assigned to treatment groups (citrate or heparin) using
block randomization stratified by center. A comprehensive
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in a confidential manner at the CIC-EC of Dijon.
Preparation of catheter locks at the hospital pharmacy
Both catheter lock solutions under study are prepared
by the pharmacy of Dijon University Hospital and pro-
vided to the pharmacy of the participating hospital, with
specific labels identifying the study, and in their original
packaging, for storage in each participating department
in the usual conditions according to the treatment attrib-
uted by randomization. The presentation of both solutions
(heparin and citrate) is identical (5 mL syringe). Special la-
bels indicating the regulatory information regarding the
clinical trials are provided by the pharmacy of the University
Hospital of Dijon and stuck to the syringe by the nurse
who prepares the catheter lock solution.
Reception, dispensing and return of study drugs will be
documented in writing in a dedicated study file kept in
the pharmacy. Units of unused study drug will be returned
to the pharmacy by the investigator after withdrawal of
the first catheter. Since the study is a double-blind design,
the investigators are unaware of the type of lock solution
being instilled in the catheter for each patient. To preserve
the blinding, the lock solution is provided in a box. The
preparation to be injected as catheter lock is prepared in a
5 mL syringe by a nurse from the unit, in isolation in a
specific room dedicated to the study procedures. The
nurse then provides the pre-prepared syringe to the phys-
ician in charge of the patient’s management, who injects
the lock solution slowly into the catheter lumen. In order
to keep the blinding intact, the nurse who prepares the
syringe with the catheter lock is not in charge of the pa-
tient’s management.
Study treatments
Citrate or heparin, according to the study group, will be
instilled into each lumen of the catheter to attain a total
volume corresponding to the volume of each branch ac-
cording to the Summary of Product Characteristics. Be-
fore each administration of citrate or heparin, the catheter
lumens will be flushed with 10 mL of saline as quickly as
possible. Then, the lock solution (heparin or citrate) will
be injected slowly (over at least 10 seconds duration) into
each lumen.
Before initiation of RRT and use of the catheter, a mini-
mum of 5 cc of liquid will be extracted from each lumen
(volume greater than the contents of each lumen). Cath-
eter patency will be verified by performing a blood return
with a 20 cc syringe. If the 20 cc syringe fills smoothly in
under four seconds, this corresponds to a blood flow of
300 mL/min on the hemodialysis machine. All catheters
used will have a minimum diameter of 13.5 French. Only
one catheter per patient will be considered for the study
analysis.Patient management
Daily monitoring of all patients will be performed in ac-
cordance with standard practices for patients undergoing
RRT. Hemodialysis catheters will be used for the purpose
of RRT only (no infusions will be administered through
the catheters). For hemodialysis catheter management,
two nurses will be present. One will work in aseptic condi-
tions (as for an operating theatre) to manage RRT initi-
ation (withdrawal of lock solution, patency check by blood
return and connection of the dialysis lines to the catheter)
and completion (remove dialysis lines, flush catheter, in-
sert catheter lock solution and bandage). The second
nurse will oversee the control panel and working of the
dialysis machine. Hemodynamic monitoring of the pa-
tient is performed continuously during RRT, including
monitoring of dialysis circuit pressures and transmem-
brane pressure.
Signs of thrombosis are recorded every time the cath-
eter is connected to the dialysis machine. Signs of infec-
tion are recorded several times daily, with measurement
of the patient’s temperature every three hours and daily
surveillance of the puncture site. Samples will be ob-
tained by swabbing the skin in case of suspected infec-
tion, in addition to blood samples. In case of suspected
or confirmed infection, the catheter will systematically
be removed and the need for antibiotic therapy will be
discussed by the medical team. If and when identified,
the germs responsible for the infection will be noted.
Bleeding complications will also be recorded, defined as
a drop in hemoglobin levels requiring transfusion of at
least two packs of red blood cells, in cases of major bleed-
ing, and number of packs of red blood cells transfused.
Insofar as possible, the catheter will be removed before
patient discharge. Patients will be followed up for the
duration of their hospital stay.
Data collection
All data will be recorded daily in the dedicated case report
form for the entire duration of the study. The following
data will be recorded:
1. for each patient: Simplified Acute Physiology Score
II, Sequential Organ Failure Assessment score at
randomization, demographic data (age, sex, weight,
height, comorbidities, clinical and microbiological
data to confirm the diagnosis of catheter-related
infection (if any)), monitoring (type of RRT,
continuous or intermittent RRT, duration of each
RRT session and use of systemic anticoagulant) and
general complications (bleeding, thrombosis or
systemic infection).
2. for each catheter: insertion date, insertion site,
catheter removal date, reason for catheter
withdrawal, use of ultrasound guidance, experience
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with under two years’ experience or senior with
more than two years’ experience), need for antibiotic
therapy due to suspected or confirmed catheter
infection, puncture site bleeding, hematoma,
thrombosis, local signs of infection and microbiology
(catheter culture, puncture site culture and blood
culture).
Study definitions
Dysfunction Catheter dysfunction is defined as the in-
ability to achieve and maintain a blood flow of more
than 200 mL/min despite changing the patient’s position,
inverting the lines and flushing with saline solution. The
occurrence of any one or more of these events (such as
a change of position, inversion of a line or flush of saline
solution) will be considered as catheter dysfunction.
Catheter thrombosis will be treated by the injection of
5,000 to 10,000 IU/mL of urokinase in each lumen of
the catheter with a volume equivalent to that of the
catheter (noted on each catheter). After 15 minutes, the
urokinase will be aspirated with a syringe and dialysis
will resume. If urokinase treatment fails to resolve cath-
eter thrombosis, the catheter will be changed [39,40].
Cather-related infections include the following:
1. Local catheter-related infection, defined as a positive
catheter-tip culture of 103 CFU/ml or more, with
the presence of pus or oozing at the catheter insertion
site, or tunnelitis.
2. General catheter-related infection, defined as a
positive catheter-tip culture of 103 CFU/ml or more,
with the disappearance of general signs of infection
within 48 hours after catheter withdrawal.
3. Catheter-related blood stream infection, defined as
the presence of fever (temperature > 38°C) and a
positive blood culture taken from the dialysis
catheter and a peripheral line in the absence of any
other source of infection, with a central-to-peripheral
quantitative blood culture ratio of over five, or a
differential period of central line culture versus
peripheral blood culture positivity for more than
two hours, with a central hemoculture showing a
positive result more quickly than a peripheral
culture.
Systematic samples will be performed at the puncture
site in case of any change in skin colour (for example,
redness) and/or the presence of pus or oozing suggest-
ive of infection. All samples will be analyzed by the bac-
teriology laboratory. If infection is confirmed, antibiotic
therapy will be initiated. A clinical event committee
comprising two physicians (Dr Aho, from the Department
of Epidemiology and Hospital Hygiene, University Hospitalof Dijon, and Professor Piroth, from the Department of
Infectiology, University Hospital of Dijon, France) blinded
to the treatment allocation will independently analyze data
and adjudicate as to the presence or not of catheter infec-
tion. Bleeding complications are defined as a drop in
hemoglobin levels requiring the transfusion of at least two
units of packed red blood cells.Study endpoints
Primary endpoint
The primary endpoint is the duration of event-free sur-
vival of the first non-tunneled dialysis catheter, defined
in days as the time from randomization to catheter with-
drawal, whatever the reason (infection, thrombosis, leakage
or deteriorated catheter and unintentional or accidental
catheter removal).Secondary endpoints
Secondary endpoints are: the rate of fibrinolysis per
1,000 catheter days, the incidence of catheter dysfunc-
tion per 1,000 catheter days, the incidence of catheter-
related infection per 1,000 catheter days, the number of
hemorrhagic events requiring the transfusion of at least
two units of packed red blood cells, length of stay in inten-
sive or critical care, length of hospital stay and in-hospital
and 28-day mortality rate.Sample size calculation
The sample size was calculated using PASS software
(version 11, Kayesville, Utah, United States), based on
several assumptions. The study by Hermite et al. [41]
compared the event-free survival of catheters with cit-
rate locks versus saline solution in ICU patients with an
indication for extracorporeal RRT. In this study, the me-
dian duration of catheter survival with citrate locking so-
lution was 12 days (interquartile range (IQR): 8 to 17],
versus six days [3-10] for catheters locked with saline so-
lution (hazard ratio (HR): 2.12, 95% confidence interval
(CI): 1.32 to 3.4), P = 0.0019). The study by Weijmer et al.
[15] reported an RR of 0.69 (95%CI: 0.44 to 1.08), P = 0.11)
for premature withdrawal of non-tunneled, uncuffed cath-
eters with citrate versus heparin. On the basis of these
findings, in the prudent hypothesis of a reduction of 25%
in the risk of catheter-related events (median of 12 days in
the citrate group versus nine days in the heparin group),
at an alpha risk of 5% and a beta risk of 20%, a total of 366
patients (183 per group) is required. Accounting for
possible crossovers between groups (less than 5%
switching from heparin to citrate) due to heparin-induced
thrombocytopenia, and allowing for patients lost to
follow-up, the final sample size is calculated to be 386
patients (193 patients included per group).
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Baseline comparability
Quantitative variables will be described as mean ± standard
deviation (SD) when normally distributed, or as median
(IQR) if non-normally distributed, and qualitative variables
as number (percentage). The baseline characteristics of
both groups will be compared by univariate analysis
(chi square or Fisher’s exact test for qualitative variables,
Student’s t-test, Mann-Whitney U test or ANOVA for
quantitative variables, as appropriate).
Primary objective
The primary analysis will be on an intention-to-treat
basis. Event-free catheter survival will be compared be-
tween groups using the log rank test. Time zero is de-
fined as the time of randomization, and the time to
withdrawal of the first non-tunneled hemodialysis cath-
eter (event-free catheter survival) will be calculated start-
ing from randomization for the analysis of the primary
endpoint. Patients will be censored in case of scheduled
withdrawal of the catheter, or death. Then, multiple Cox
regression analysis will be performed as appropriate, to
take into account any potential imbalances in potential
confounders between groups. Treatment effects will be
expressed as HRs with 95% CI. P values will also be pro-
vided. A per-protocol analysis will also be performed,
using the same techniques. For the per-protocol analysis,
patients will be grouped according to the treatment ac-
tually received.
An interim analysis is planned once 50% of the expected
number of patients has been included (after inclusion of
200 patients). The time between randomization and with-
drawal of the catheter will be described in both groups
and compared using the log rank test, with an alpha risk
fixed at 0.0001 (according to the method proposed by Peto
et al. [42], to avoid inflating the alpha risk of the main
analysis at the end of the study).
Secondary objectives
Secondary endpoints will be compared using the chi
square test, Fisher’s exact test, Student’s t-test, or the
Mann-Whitney U test, as appropriate. Treatment ef-
fects will be presented with 95% CI. All analysis will be
performed using SAS version 9.2 (SAS Institute Inc.,
Cary, North Carolina, United States).
Study organization
Data and Safety Monitoring Board
An independent Data and Safety Monitoring Board
(DSMB) will monitor the safety and efficacy of the trial
and periodically assess whether the trial should continue
to the planned termination. Based on the safety data, the
DSMB may recommend modifications to the protocol
(for example amendments or termination of the study),and, when needed, the DSMB will decide on stopping
rules. They will declare any conflicts of interest if such
should arise. The DSMB will report to the chairman of
the steering committee, who in turn is responsible for
implementing a decision to terminate the trial prema-
turely if deemed necessary.
Discussion
This study will provide an evidence base for recommenda-
tions regarding the use of anticoagulant catheter locks in
the prevention of dysfunction in non-tunneled hemodialysis
catheters in patients in critical or intensive care with AKI.
Current literature is sparse on this topic, with only one
randomized study to date [41].
Two types of hemodialysis catheters are used in clin-
ical practice, firstly, temporary catheters (non-tunneled),
whose use is limited to a few days, and secondly, long-
term catheters (tunneled), which can be left in place for
up to several months. In the context of this study, we
will only deal with temporary, non-tunneled catheters.
Indeed, tunneled catheters can be left in place for longer
periods, and are thus more suitable for use in chronic
hemodialysis patients. We chose to limit our analysis to
non-tunneled catheters, which are inserted for shorter
time periods and are mainly used in the setting of AKI.
Catheters with these features meet the needs of urgent
RRT and are suitable for short-term use because they are
quick and relatively easy to put in place [43], and they
currently represent standard practice in critical care.
There is abundant literature regarding the optimum
management of tunneled catheters in patients undergo-
ing long-term hemodialysis, but data is scarce regarding
the use of non-tunneled catheters in the ICU setting. For
this reason, we focused our investigations on patients with
AKI, and not patients requiring long-term RRT.
Although heparin is approved for use as a catheter
lock in France, there is insufficient evidence in the litera-
ture regarding its safety and efficacy in patients in the
critical or intensive care settings. Conversely, there are
ample reports concerning the use of trisodium citrate
4% as a catheter lock in tunneled catheters in long-term
hemodialysis patients, to prevent catheter dysfunction
and infection [28,34-37]. Thus, it would appear logical
that citrate could hold promise for the patient popula-
tion in our study, notably for those with a contraindica-
tion to heparin. Yet, citrate is not approved for use in
this indication in France.
In the ICU setting, there are a number of different def-
initions of dialysis catheter dysfunction, and almost all
are applicable in patients on intermittent RRT [41,44].
In clinical practice, temporary dialysis catheter dysfunc-
tion can be defined as the failure to attain and maintain
blood flow through the dialysis catheter sufficient for the
administration of an adequate RRT dose [45]. Dysfunctions
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and may even require that the catheter be changed. In
the literature, the incidence of dysfunction depends
largely on the type of catheter being used, its size, the
anti-thrombotic catheter lock, the patient’s characteris-
tics, the type of therapy and catheter maintenance [48].
In a study by Hryszko et al., the frequency of catheter
dysfunction was 31.5% [44]. In the French Cathedia
study, when only first dialysis catheter placement was
assessed, the rate of dysfunction was 10.7% [49].
Infection of the dialysis catheter is a major challenge
and can be responsible for 50 to 70% of catheter with-
drawals [15,36]. The incidence of infectious complications
in dialysis catheters varies between reports, depending on
the catheter type and the population studied. However, it
is estimated that the incidence of catheter-related infec-
tions (including local infection and bacteremia) is between
two and 14 events per 1,000 catheter days, with a median
of six [15,41,49]. Repeated handling and catheter replace-
ment over a metal guide in case of dysfunction increases
the risk of infection [46,47]. Catheter-related infections
are associated with increased length of stay, increased risk
of death and higher cost of care [50,51]. Infections can be
prevented by the strict respect of aseptic conditions at the
time of catheter insertion.
A limitation of our study is that no analysis of the
costs related to the use of citrate as a catheter lock solu-
tion (such as cost-efficacy, cost-effectiveness, absolute
costs) is planned. Our working hypothesis is that triso-
dium citrate 4% will be shown to be superior to heparin
in terms of risk of catheter dysfunction in non-tunneled
hemodialysis catheters. The potential implications of this
study are clearly important in the fields of critical and
intensive care.
Trial status
The trial is currently recruiting patients. The recruitment
process started on 14 June 2013 and at the time of sub-
mission, 191 patients have been recruited. The estimated
duration of the inclusion period is 24 months.
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